Biocryst Pharmaceuticals Inc [BCRX] stock is trading at $7.82, down -4.52%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BCRX shares have gain 10.84% over the last week, with a monthly amount glided 4.83%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, RBC Capital Mkts upgraded its rating to Outperform on September 18, 2023, and elevated its price target to $10. On August 04, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $11 on the stock. BofA Securities upgraded its rating to a Buy but stick to its price target of $10 on July 13, 2023. Needham upgraded its rating to a Buy but $14 remained the price target by the analyst firm on February 22, 2023. Evercore ISI upgraded its rating to Outperform for this stock on November 02, 2022, and upped its price target to $16. In a note dated August 05, 2022, Oppenheimer downgraded an Perform rating on this stock.
Biocryst Pharmaceuticals Inc [BCRX] stock has fluctuated between $4.03 and $8.88 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Biocryst Pharmaceuticals Inc [NASDAQ: BCRX] shares were valued at $7.82 at the most recent close of the market. An investor can expect a potential return of 104.6% based on the average BCRX price forecast.
Analyzing the BCRX fundamentals
Biocryst Pharmaceuticals Inc [NASDAQ:BCRX] reported sales of 412.58M for the trailing twelve months, which represents a growth of 34.98%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -0.1%, Pretax Profit Margin comes in at -0.3%, and Net Profit Margin reading is -0.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is 0.26 and Total Capital is -0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.65 points at the first support level, and at 7.49 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.11, and for the 2nd resistance point, it is at 8.41.
Ratios To Look Out For
For context, Biocryst Pharmaceuticals Inc’s Current Ratio is 2.78. Further, the Quick Ratio stands at 2.73, while the Cash Ratio is 0.63. Considering the valuation of this stock, the price to sales ratio is 3.93.
Transactions by insiders
Recent insider trading involved McKee Amy E, Director, that happened on Jun 24 ’24 when 8600.0 shares were sold. Director, SANDERS MACHELLE completed a deal on Jun 17 ’24 to sell 4689.0 shares. Meanwhile, Director HEGGIE THERESA sold 6698.0 shares on Jun 14 ’24.
